Eli Lilly and Company
RELATED ARTICLES
Researcher Profile: Jim Martinez, MD
Promising results from clinical trials of CGRP inhibitors bring renewed hope for patients with cluster headache.
A New Era In Treatments For Migraine
Reducing unnecessary suffering resulting from migraine is beneficial to both individual patients and to society.
Researcher Profile: Christina Kiley
Through her roles at Eli Lilly and Company, Dr. Christina Kiley developed a strong understanding of the patient perspective and the diverse ways patients are incorporated into biopharmaceutical research.
Disrupting Alzheimer's Disease
Researchers, patient advocates and policymakers recently gathered in Chicago to discuss the unique challenges that make up Alzheimer's research and what the future holds for the 5.7 million Americans living with the disease.
Innovation is Fragile, But Worth Protecting
The Atlantic, in partnership with PhRMA's GOBOLDLY campaign, convened thought leaders to discuss the policies needed to foster biopharmaceutical innovation while ensuring access and affordability for patients.
Researcher Profile: Jirong Lu
Dr. Jirong Lu, a distinguished research fellow at Eli Lilly and Company (Lilly), traces the beginnings of her career to a high school fascination with chemistry.
Getting Ahead of Migraines
Understanding migraines fully can give patients back time taken by the disease.
Migraine: More than Just a Bad Headache
Migraine is a debilitating neurological disease that is often misunderstood by those who do not suffer symptoms, according to the Migraine Impact Report, a new survey recently released by Eli Lilly and Company and conducted by Nielsen.
Researcher Profile: Laura Michael
Dr. Laura Michael started her career at Lilly researching cardiovascular disease and the complications that frequently arise from it.
From Technology to Treatment: Uncovering Cures for Brain Diseases
The brain is one of the most complex – and most fascinating – organs in the human body, and one that can be impacted by countless diseases and disorders.
Combating Type 2 Diabetes
New innovative treatments are revolutionizing life for patients battling diabetes.
Advancing Innovation in San Diego
As a senior research advisor at the Eli Lilly and Co. Biotechnology Center in San Diego, Stephen Demarest delivers innovative and novel therapeutics to treat challenging diseases such as cancer and autoimmunity.
Researcher Profile: Dan Skovronsky
A neuroscientist and neuropathologist by training, Dan is responsible for development across all of Lilly's products - from clinical trials through approvals - specifically working within the areas of oncology, diabetes, Alzheimer's disease, immunology and pain management.
On the Front Lines of Science
In recent years, medical breakthroughs including new drug therapies and early disease monitoring technologies have accelerated rapidly. This has created wide-ranging transformations in patient care.
America's Biopharmaceutical Industry Is Central to Diverse R&D Ecosystem
America's biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that supports continued medical advances for patients.
Research Doesn’t End On A Medicine’s Approval
Research on a medicine doesn't end on the initial approval by the FDA. Eli Lilly and Company's chief medical officer shares why ongoing research helps us better understand a medicine's full value.
POPULAR ARTICLES
HIV/AIDS: From An Acute Fatal Disease to A Chronic, Manageable Condition
<p>The evolution of HIV/AIDS treatment is nothing short of remarkable. In the 1980s, HIV/AIDS was an acute fatal disease. Today it is a chronic, manageable condition thanks to the commitment of biopharmaceutical researchers, health care workers and advocates.</p>
READ MORE
Combatting Sickle Cell Disease with Cell & Gene Therapy
<p><span><span><span><a><span lang="EN"><span>America's biopharmaceutical companies are researching and developing new treatments to alleviate the tremendous burden of this devastating and painful disease and to improve the quality of life for sickle cell patients.</span></span></a></span></span></span></p>
READ MORE
Why Has Research into Alzheimer's Disease Been So Hard?
<p>Why, when we have seen such progress in our ability to treat other diseases, such as cancer, diabetes and HIV, has progress in Alzheimer's research been so difficult to achieve?</p>
READ MORE
5 Recent Developments Advancing Vaccines
As communities continue to grapple with the impact of COVID-19, vaccines have once again come to the forefront as a critical health care tool.
READ MORE
The Innovation Ecosystem Fuels Breakthroughs
Biopharmaceutical research companies are uniquely positioned to take the necessary risks to further advance research into safe and effective treatments for patients.
READ MORE
Understanding mRNA Vaccines
Scientists at Pfizer are breaking barriers with mRNA technology, one of the approaches used to develop COVID-19 vaccines.
READ MORE
Protecting Alzheimer's Research
15 million people will live with Alzheimer's by 2060. We're working to change that.
READ MORE